MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
2seventy bio, Inc. (NASDAQ: TSVT)*
Organization & Developments: 2seventy bio
Parents
2seventy bio, Inc. (NASDAQ: TSVT)*
Children
2022: 2seventy bio A Buy For Abecma And CAR T Platfor_ seekingalpha.com
2022: 2seventy bio: This Spinoff In The CAR-T Space Is Attractive_seekingalpha.com
2022: 2seventy bio's honeymoon phase is over as job cuts hit 6% of staff
2023: 2seventy eliminates 40% of roles, seeks replacement for CEO Nick Leschly as cell therapy falters
2024: 2seventy bio: All In On Abecma Multiple Myeloma Treatment
2024: 2seventy bio: An Overload Of Troubles At This Small Pharma_ seekingalpha.com
2024: 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround_seekingalpha.com
2024: Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma
2024: Struggling 2Seventy scraps a key cancer study
2025: 2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
Jumps
Finance & Acquisitions: 2seventy bio
Key People: 2seventy bio